Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

Université Laval

$100,000.00

Correction of the DMD gene with the CRISPR/Cas9 technology: restoring the reading frame and production of a dystrophin protein with an adequate structure.

FY 2016-17

Summary
The long-term aim of the project is to develop a therapy for Duchenne Muscular Dystrophy (DMD) patients having any point mutation, duplication or exon deletion in the dystrophin gene between exons 48 and 57. This will be done by correcting the dystrophin gene directly in the muscle fibers of the patients using the new CRISPR/Cas9 technology. This technology permits to target with a guide RNA (gRNA) a sequence of 20 nucleotides located anywhere in the human genome to induce with the newly engineered eSaCas9 nuclease a double strand break of the DNA at that specific site. We will target with two gRNAs specific sequences in exons 47 and 58 of a dystrophin gene to induce a deletion of the gene between these 2 sites and create a hybrid exon 47-58. I have already been able to modify with the CRISPR technology the dystrophin gene in myoblasts of a DMD patient and in the hDMD mouse model containing the complete human dystrophin gene. We will investigate this proposed treatment in myoblasts from 3 DMD patients with different deletions (i.e., deletions of exons 49 to 50, 51 to 53, 51 to 56). Starting from the hDMD transgenic mouse, we will also develop a new mouse model with a deletion of exon 50 resulting in a frame shift, the absence of the dystrophin protein and thus in a dystrophic phenotype. We will inject i.v. this mouse model with an AAV9 coding for eSaCas9 gene and 2 sgRNAs. The formation of the hybrid exon 47-58 in dystrophin gene will permit the expression an internally deleted but fully functional dystrophin protein preventing muscle fiber damage during contraction and thus stopping the progression of the muscle weakness. This therapy will require a single intervention (i.e., injection of the an AAV virus coding for Cas9 and 2 gRANs) and will be permanent.
Program
Project Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
366623
Name
Tremblay Jacques P
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Correction of the DMD gene with the CRISPR/Cas9 technology: restoring the reading frame and production of a dystrophin protein with an adequate structure.
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Crispr/Cas9; Duchenne Muscular Dystrophy; Gene Correction; Gene Therapy; Hereditary Disease
Abstract
The long-term aim of the project is to develop a therapy for Duchenne Muscular Dystrophy (DMD) patients having any point mutation, duplication or exon deletion in the dystrophin gene between exons 48 and 57. This will be done by correcting the dystrophin gene directly in the muscle fibers of the patients using the new CRISPR/Cas9 technology. This technology permits to target with a guide RNA (gRNA) a sequence of 20 nucleotides located anywhere in the human genome to induce with the newly engineered eSaCas9 nuclease a double strand break of the DNA at that specific site. We will target with two gRNAs specific sequences in exons 47 and 58 of a dystrophin gene to induce a deletion of the gene between these 2 sites and create a hybrid exon 47-58. I have already been able to modify with the CRISPR technology the dystrophin gene in myoblasts of a DMD patient and in the hDMD mouse model containing the complete human dystrophin gene. We will investigate this proposed treatment in myoblasts from 3 DMD patients with different deletions (i.e., deletions of exons 49 to 50, 51 to 53, 51 to 56). Starting from the hDMD transgenic mouse, we will also develop a new mouse model with a deletion of exon 50 resulting in a frame shift, the absence of the dystrophin protein and thus in a dystrophic phenotype. We will inject i.v. this mouse model with an AAV9 coding for eSaCas9 gene and 2 sgRNAs. The formation of the hybrid exon 47-58 in dystrophin gene will permit the expression an internally deleted but fully functional dystrophin protein preventing muscle fiber damage during contraction and thus stopping the progression of the muscle weakness. This therapy will require a single intervention (i.e., injection of the an AAV virus coding for Cas9 and 2 gRANs) and will be permanent.
Competitiondate
201611
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tremblay, Jacques P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
Université Laval - $100,000 Grant (2016-17) | Canada Spends